Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -13.64% is 80% above its 5-year average of -69.74%, near the high end of its 5-year range (-150.37%–-9.95%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.39% above its 12-month average of -16.31%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -13.64%.
RETURN ON EQUITY (ROE)
-13.64%
RETURN ON EQUITY (ROE) AVG TTM
-16.31%
RETURN ON EQUITY (ROE) AVG 3Y
-70.07%
RETURN ON EQUITY (ROE) AVG 5Y
-69.74%
RETURN ON EQUITY (ROE) AVG 10Y
-72.63%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.39%
CURRENT VS 3Y AVG
+80.54%
CURRENT VS 5Y AVG
+80.45%
CURRENT VS 10Y AVG
+81.22%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
+66.90%
vs the sector median at left
Monopar Therapeutics Inc.
Market Cap
$530.03M
Return on Equity (ROE)
-13.64%
TTM Avg
-16.31%
3Y Avg
-70.07%
5Y Avg
-69.74%
Market Cap
$530.71M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
Market Cap
$535.09M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$535.43M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$535.61M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$536.32M
Return on Equity (ROE)
N/A
TTM Avg
6.49%
3Y Avg
6.51%
5Y Avg
-75.00%
Market Cap
$521.71M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$540.02M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
Market Cap
$540.91M
Return on Equity (ROE)
-24.90%
TTM Avg
-76.97%
3Y Avg
-68.04%
5Y Avg
-50.09%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $530.03M | -13.64% | -16.31% | -70.07% | -69.74% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $530.71M | N/A | 91.17% | 180.92% | 76.31% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $535.09M | N/A | 44.05% | 44.05% | 44.05% |
| Delcath Systems, Inc. (DCTH)vs › | $535.43M | 0.44% | -17.98% | 71.24% | -6.51% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | -60.79% | -73.94% | -62.04% | -71.62% |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | 6.49% | 6.51% | -75.00% |
| Immix Biopharma, Inc. (IMMX)vs › | $521.71M | -17.44% | -97.25% | -87.77% | -77.06% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $540.02M | -306.61% | -169.61% | -163.97% | -73.13% |
| Shattuck Labs, Inc. (STTK)vs › | $540.91M | -24.90% | -76.97% | -68.04% | -50.09% |
| Altimmune, Inc. (ALT)vs › | $517.30M | -19.35% | -58.07% | -51.86% | -46.32% |
ROE
-13.6%
ROA
-13.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -13.64% |
| 2026-03-31 | -11.07% |
| 2025-12-31 | -9.95% |
| 2025-09-30 | -13.73% |
| 2025-06-30 | -33.16% |
| 2025-03-31 | -30.92% |
| 2024-12-31 | -28.32% |
| 2024-09-30 | -130.89% |
| 2024-06-30 | -116.98% |
| 2024-03-31 | -101.76% |
| 2023-12-31 | -150.37% |
| 2023-09-30 | -143.46% |
| 2023-06-30 | -126.72% |
| 2023-03-31 | -117.32% |
| 2022-12-31 | -104.22% |
| 2022-09-30 | -82.33% |
| 2022-06-30 | -71.36% |
| 2022-03-31 | -57.03% |
| 2021-12-31 | -48.06% |
| 2021-09-30 | -40.19% |
| 2021-06-30 | -33.11% |
| 2021-03-31 | -28.28% |
| 2020-12-31 | -40.18% |
| 2020-09-30 | -30.77% |
| 2020-06-30 | -36.86% |
| 2020-03-31 | -31.78% |
| 2019-12-31 | -33.46% |
| 2019-09-30 | -84.50% |
| 2019-06-30 | -74.35% |
| 2019-03-31 | -64.55% |
| 2018-12-31 | -46.64% |
| 2018-09-30 | -40.27% |
| 2018-06-30 | -212.81% |
| 2018-03-31 | -192.58% |
| 2017-12-31 | -172.10% |
| 2017-09-30 | -157.52% |
| 2017-06-30 | -36.13% |
| 2017-03-31 | -43.18% |
| 2016-12-31 | -41.88% |
